Revvity (NYSE:RVTY) Posts Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Revvity beat Q1 estimates with adjusted EPS of $1.06 vs. $1.02 and revenue of $711.1M (up 7% y/y), but trimmed FY2026 adjusted EPS guidance to $5.20–$5.30, roughly a $0.15 reduction that signals lower near‑term upside.
• Management signed a letter of intent to divest the China immunodiagnostics business (~6% of 2025 revenue) with a planned closing by end‑2027, which should improve pro forma growth and margins but will cause ~4.5% revenue dilution and timing uncertainty until closing.
• Financials and capital allocation remain solid: Q1 free cash flow was $115M (~97% conversion of adjusted net income), the company repurchased $86M of stock, holds net leverage around 2.8x, and plans a ~€600M bond repayment in July.

Revvity (NYSE:RVTY - Get Free Report) released its earnings results on Tuesday. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04, FiscalAI reports. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $711.12 million during the quarter, compared to analyst estimates of $704.20 million. During the same period in the prior year, the firm posted $1.01 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. Revvity updated its FY 2026 guidance to 5.200-5.300 EPS.

Here are the key takeaways from Revvity's conference call:

• Signed a letter of intent to divest the China immunodiagnostics business (≈6% of 2025 revenue), expects a definitive agreement within ~2 months and closing by end of 2027, and says the move will reweight China to ~8%–9% of revenue and boost 2026 pro forma organic growth ~100 bps and margins ~30 bps.
• Revvity beat Q1 expectations with 3% organic growth, adjusted operating margin of 23.6% and adjusted EPS of $1.06; excluding the China immunodiagnostics business, Q1 pro forma results would have been ~6% organic growth and a 24% pro forma margin.
• Software and AI are core growth drivers: the company launched Xynthetica, BioDesign, and LabGistics this year, reports SaaS/ARR growth north of 30%–40% year‑over‑year and says internal AI deployment (cited by Gartner) is accelerating product delivery and employee productivity.
• Balance sheet and cash generation remain strong — Q1 free cash flow was $115M (≈97% conversion of adjusted net income), the company repurchased $86M of stock in the quarter, finished with net leverage ~2.8x and plans to repay a ~€600M bond in July.
• Near‑term financial impact: management lowered reported 2026 adjusted EPS by roughly $0.15 to a pro forma range of $5.20–$5.30 (the guide excludes any sale proceeds), and the planned divestiture reduces previously expected 2026 revenue by ~4.5%, creating short‑term dilution and timing uncertainty until closing.

Revvity Stock Up 2.5%

RVTY opened at $88.71 on Tuesday. Revvity has a 1 year low of $81.22 and a 1 year high of $118.30. The firm has a 50 day moving average price of $90.39 and a 200 day moving average price of $96.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. The company has a market cap of $9.92 billion, a PE ratio of 42.65, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th. Revvity's dividend payout ratio is 13.46%.

Institutional Investors Weigh In On Revvity

Several large investors have recently made changes to their positions in RVTY. Price T Rowe Associates Inc. MD raised its stake in shares of Revvity by 5.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company's stock valued at $832,693,000 after acquiring an additional 434,570 shares during the period. Morgan Stanley increased its holdings in Revvity by 29.6% in the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company's stock valued at $275,202,000 after purchasing an additional 650,083 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Revvity by 22.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company's stock valued at $252,727,000 after purchasing an additional 486,159 shares during the period. Invesco Ltd. lifted its stake in shares of Revvity by 15.7% during the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company's stock worth $223,816,000 after purchasing an additional 346,313 shares in the last quarter. Finally, UBS Group AG lifted its stake in shares of Revvity by 22.3% during the third quarter. UBS Group AG now owns 2,179,505 shares of the company's stock worth $191,034,000 after purchasing an additional 397,160 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wells Fargo & Company upped their price objective on shares of Revvity from $107.00 to $110.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 3rd. The Goldman Sachs Group lowered their target price on shares of Revvity from $110.00 to $95.00 and set a "neutral" rating for the company in a report on Tuesday, April 14th. TD Cowen reaffirmed a "hold" rating on shares of Revvity in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. cut their price target on shares of Revvity from $105.00 to $96.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 31st. Finally, Robert W. Baird decreased their price target on shares of Revvity from $129.00 to $125.00 and set an "outperform" rating on the stock in a report on Monday. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $109.36.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.06 vs. $1.02 estimate and revenue of $711.1M (up 7% y/y), demonstrating near-term operational strength. Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
• Neutral Sentiment: The company provided supplemental materials and a conference call for details (slides and press release available), which will drive near-term investor attention as markets digest the guidance details. View Press Release
• Neutral Sentiment: An analyst note lowered Revvity’s price target (Robert W. Baird cut to $125 but kept an outperform rating), a mixed signal—less optimism on upside but continued conviction on longer-term growth. Price Target Cut to $125.00 by Analysts at Robert W. Baird
• Neutral Sentiment: Brokerage consensus sits around a “Hold,” indicating analysts are cautious until the company’s FY guidance and end-market trends (notably China and academic demand) clarify. Revvity Inc. Given Average Recommendation of "Hold" by Brokerages
• Negative Sentiment: FY2026 guidance disappointed: EPS guidance of $5.20–$5.30 vs. ~5.40 consensus and revenue guidance near $2.8B (below the ~$3.0B expectation) — the main driver of the stock decline as it reduces near-term upside for estimates. Revvity to Report Q1 Earnings: What's in Store for the Stock?

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.